Related Experiment Video
Updated: May 16, 2026

High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity
Published on: November 16, 2016
Rhabdomyolysis caused by an unusual interaction between azithromycin and simvastatin
Gaurav Alreja1, Saqib Inayatullah, Saurabh Goel
1Department of Medicine, Baystate Medical Center, Tufts University School of Medicine, Springfield, MA, USA.
Abstract:
Rhabdomyolysis is an uncommon but life-threatening adverse effect of simvastatin therapy. A 73-year-old male on chronic simvastatin therapy received azithromycin for acute bronchitis. He presented with weakness of all extremities with a significant increase in creatinine phosphokinase levels and acute kidney injury. Simvastatin was stopped and supportive therapy with intravenous saline and bicarbonate was initiated. The serum creatinine and creatine phosphokinase returned to baseline in the next 7 days. Two months later, simvastatin was resumed without any recurrence of symptoms. Our case report highlights the rare description of rhabdomyolysis caused by a drug interaction between simvastatin with azithromycin.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Drug toxicity: Drug–Drug Interaction
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Pharmacokinetics: Drug–Drug Interactions
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Drug toxicity: Idiosyncratic Reactions
